Canadians’ data heading to ASCO

Versant Partners analyst Doug Loe has compiled a list of six biotech companies that will have data presented at the American Society of Clinical Oncology meeting on June 4 to 8.  He expects: · AEterna Zentaris (NASDAQ:AEZS; TSX:AEZ) to report final data from its 43-patient Phase 2 advanced ovarian cancer trial with its AEZS-108 drug, [...]

Oncolytics ready for final step with Reolysin

After a 10-year journey, Oncolytics Biotech (TSX:ONC; NASDAQ:ONCY ) is ready to take the final clinical step with its sole Reolysin drug as a treatment for a broad range of cancers. “Our product has really shown a breadth of activity in a wide variety of cancers that we had hoped it would way back when [...]

Oncolytics gets rights to potential cancer drug

Oncolytics Biotech (TSX: ONC; NASDAQ: ONCY) of Calgary has swung a deal for a stake in closely-held British Canadian Biosciences, including potential rights to purchase BCB’s oncology product, which  is entering Phase 2 studies to treat solid tumours. Under the accord, Oncolytics purchased all of the convertible preferred shares of BCB in exchange for 200,000 common [...]